Galmed Pharmaceuticals Ltd.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: IL0011313900

USD

1.13

0.17 (17.84%)

Dec 04

NAS

Click here to see other stocks

Company CV

About Galmed Pharmaceuticals Ltd.

stock-summary

Galmed Pharmaceuticals Ltd.

Pharmaceuticals & Biotechnology

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Company Coordinates

Company Details

16 Ze'ev Tyomkin St. (4Th Fl.) , TEL AVIV-YAFO None : 6578317

stock-summary

Tel: 972 3 6938448

stock-summary

http://www.galmedpharma.com

stock-summary

Registrar Details

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Board of Directors

Management

Designation

Mr. Allen Baharaff

President, Chief Executive Officer, Director

Dr. David Sidransky

Lead Independent Director

Mr. Marshall Heinberg

Director

Prof. Ran Oren

Director

Dr. Carol Brosgart

Independent Director

Mr. William Marth

Independent Director

Stock DNA

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 8 Million ()

P/E

NA (Loss Making)

Industry P/E

NA

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-34.36%

Price to Book

0.37